Ravagalimab

DB16676InvestigationalProtein Based Therapies

Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis...

Mechanism: Pharmacologically active on CD40 ligand
Curator reviewed
Code names: ABBV-323 · PR-1629977

Resolves to

Compound

UNIIYGF9TW3QZJCAS2050816-56-1

Targets

P29965CD40LG

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ravagalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account